154257-81-5

Basic information

• Product Name: 5-Chloro-2-Methyl-3-nitro-benzoic acid
• Synonyms: 5-Chloro-2-Methyl-3-nitro-benzoic acid;5-Chloro-3-nitro-o-toluic acid, 3-Carboxy-5-chloro-2-methylnitrobenzene
• CAS NO: 154257-81-5
• Molecular Formula: C₈H₆ClNO₄
• Molecular Weight: 215.59054
• Mol File: 154257-81-5.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 352.1±42.0 °C(Predicted)
• Appearance: /
• Density: 1.517±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.66±0.20(Predicted)
• CAS DataBase Reference: 5-Chloro-2-Methyl-3-nitro-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-2-Methyl-3-nitro-benzoic acid(154257-81-5)
• EPA Substance Registry System: 5-Chloro-2-Methyl-3-nitro-benzoic acid(154257-81-5)

Safety Data

• Hazardous Substances Data: 154257-81-5(Hazardous Substances Data)

Usage

Description

5-Chloro-2-Methyl-3-nitro-benzoic acid is an organic compound characterized by its chlorine, methyl, and nitro functional groups attached to a benzoic acid backbone. This chemical structure endows it with specific properties that make it suitable for various applications in different industries.

Uses

Used in Pharmaceutical Industry:
5-Chloro-2-Methyl-3-nitro-benzoic acid is used as a key intermediate in the synthesis of benzene piperidine derivatives. These derivatives are important for the development of various pharmaceutical compounds due to their potential biological activities and therapeutic applications.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-Chloro-2-Methyl-3-nitro-benzoic acid serves as a versatile building block for creating a wide range of chemical products. Its unique functional groups allow for further reactions and modifications, leading to the production of various specialty chemicals and materials.
Used in Research and Development:
5-Chloro-2-Methyl-3-nitro-benzoic acid is also utilized in research and development settings for studying the effects of different functional groups on the properties and reactivity of organic compounds. This knowledge can be applied to design and develop new molecules with specific characteristics and applications.

Upstream product

• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 7499-06-1 5-chloro-2-methylbenzoic acid 

Downstream Products

• 1207455-25-1 methyl 2-(bromomethyl)-5-chloro-3-nitrobenzoate 
• 1207455-28-4 (E)-4-(benzylideneamino)-6-chloroisobenzofuran-1(3H)-one 
• 1207455-29-5 ethyl 7-chloro-3-(1-methyl-1H-imidazol-2-yl)-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinoline-5-carboxylate 
• 1403595-44-7 tert-butyl 4-((5-chloro-3-(methoxycarbonyl)-2-methylphenyl)(methyl)amino)piperidine-1-carboxylate 
• 1403595-34-5 5-chloro-3-[ethyl(1-methylpiperidin-4-yl)amino]-2-methylbenzoic acid 
• 1403595-33-4 methyl 5-chloro-3-[ethyl(1-methylpiperidin-4-yl)amino]-2-methylbenzoate 
• 1403595-32-3 tert-butyl 4-((5-chloro-3-(methoxycarbonyl)-2-methylphenyl)-(ethyl)-amino)piperidine-1-carboxylate 
• 294190-18-4 methyl 3-amino-5-chloro-2-methylbenzoate 
• 1403597-77-2 methyl 3-(((trans)-4-((tert-butoxycarbonyl)amino)cyclohexyl)amino)-5-chloro-2-methylbenzoate 
• 1403597-67-0 methyl 3-(((cis)-4-((tert-butoxycarbonyl)amino)cyclohexyl)amino)-5-chloro-2-methylbenzoate 
• 1403596-77-9 C₁₅H₂₀ClNO₃ 
• 1403596-76-8 methyl 5-chloro-2-methyl-3-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)benzoate 
• 1403596-75-7 methyl 5-chloro-2-methyl-3-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzoate 
• 1403591-31-0 5-chloro-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-3-(methyl((tetrahydro-2H-pyran-4-yl)methyl)amino)benzamide 

Relevant articles and documents

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA

The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is -CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl- (C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or -ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Posttranslational methylation of histones plays a critical role in gene regulation. Misregulation of histone methylation can lead to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor in clinical development, has shown activity in both preclinical models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors. Herein we report the structure-activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clinical development. The importance of several methyl groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.